How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree on the proposal for withdrawing this technology appraisal? If not, please can you state why you disagree.

  • Question on Consultation

    Are you aware of any implications for UK clinical practice on withdrawing this technology appraisal? If so, please describe.

2025 withdrawal proposal for pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma (TA306)

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Methods

The withdrawal surveillance review process consisted of:

  • Considering whether the conditions under which NICE should withdraw TA guidance as stated in section 8.2.19 of the NICE health technology evaluations manual are met.

  • Considering the availability of NICE guidance and other UK guidance and support.

  • Considering the implications of withdrawing the TA in terms of system impact; population impact; health inequalities; budget impact; and NICE organisational needs.